Navigation Links
EURTAC Phase III study: Erlotinib nearly doubles progression-free survival vs. chemotherapy
Date:7/5/2011

In the first phase III study to include Western lung cancer patients, first-line treatment with erlotinib (Tarceva) nearly doubled progression-free survival compared with chemotherapy, according to research presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer (IASLC).

Erlotinib is a tyrosine kinase inhibitor (TKI) that targets the epidermal growth factor receptor (EGFR). Non-small cell lung cancer (NSCLC) patients with EGFR activating mutations tend to respond well to TKI therapy.

"Although a growing body of evidence has been emerging about this type of lung cancer, almost all of the studies have been conducted in Asian patients, a group that historically has had significantly different results to NSCLC therapy compared to Western populations," said principal investigator Dr. Radj Gervais, M.D., of the Centre Franois Baclesse in Caen, France. "EURTAC is the first Phase III study with first-line erlotinib in Western patients with this genetically distinct type of advanced NSCLC."

Researchers tested more than 1,000 patients over a five-year-period to find the study population of 174 patients, which were randomly assigned to receive erlotinib or platinum-based chemotherapy.

The response rate to erlotinib was 54.5%, compared with 10.5% to chemotherapy, according to preliminary results. Progression-free survival in the erlotinib arm was 9.4 months, compared with 5.2 months in the chemotherapy arm. Median survival was 22.9 months in the erlotinib arm and 18.8 months in the chemotherapy arm.

"Our results showed that first-line erlotinib nearly doubled progression-free survival; that's a significant improvement over chemotherapy, with a better tolerability profile," Dr. Gervais said. "We now have results for the use of first-line erlotinib in Asian and Western EGFR mutation-positive patients with NSCLC, and so we can carry this knowledge into our daily practice. I think EURTAC really is a big step towards individualized lung cancer care."


'/>"/>

Contact: Rene McGaw
renee.mcgaw@ucdenver.edu
31-205-493-413
International Association for the Study of Lung Cancer
Source:Eurekalert

Related medicine news :

1. Medical Imaging Northwest Completes Phase I of Its Healthcare IT Integration to Maintain Patient Care Improvements
2. New High Purity Immunoglobulin Enters Phase III in Europe and the US
3. Poniard Pharmaceuticals Presents Positive Survival Data from a Phase 2 Clinical Study of Picoplatin in Metastatic Prostate Cancer at the 2010 American Society of Clinical Oncology Genitourinary Cancers Symposium
4. Nuvo Research enrolls first patient in Phase 2 WF10 allergic rhinitis trial
5. Askthedoctor.com Makes Medical Information More Accessible to the Public by Completing Phase 1 of US Expansion
6. Intellicate Announces New “Phased Return to Work” (PRtW) Service
7. Southampton scientists begin Phase II patient trial for new asthma treatment
8. Pilot Testing Phase Ends; Expansion Of Sales Force Begins
9. New phase II study supports potential of gs-9450 as new treatment option for steatohepatitis
10. Phase II study of an oral therapy for Gaucher disease yields positive results
11. Accumed Research Associates Expands Capabilities In Phase I and Bioequivalence Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... , ... Sandbox, one of the nation’s leading independent full-service ... created position of executive vice president, chief creative officer.     , In his new ... LA offices. He reports to Nancy Finigan, president of those offices. , “As ...
(Date:5/3/2016)... ... May 03, 2016 , ... University of the ... the launch of its Associates and Bachelor's degrees in Health Studies. Leading figures ... University, Dr. Torsten N. Wiesel; Chairman and CEO of Fortune 500® company Henry ...
(Date:5/3/2016)... ... , ... Each year, about 800,000 people suffer from cerebral vascular accidents, or ... account for one death every four minutes. Many people who survive a stroke ... launching a video series called “Your Brain,” in conjunction with its medical journal “Balance,” ...
(Date:5/3/2016)... ... May 03, 2016 , ... For the sixth consecutive ... Communication Technology (ICT) companies in the annual Branham300 listing. For 23 years, the ... as ranked by revenue. , “We are honored to be on the ...
(Date:5/3/2016)... ... ... Branches, Inc. is proud to have been selected as a Macy’s grant ... Miami. Macy’s is a wonderful community partner and has helped to support Branches’ student ... and academic support to elementary students 5 days a week. Summer Shade, a 7 ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016   Click ... Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s largest ... signed a definitive agreement to acquire Valley Campus ... Pharmacy ("TNH"), a leading specialty pharmacy that provides ... Nuys, California . In 2015, TNH generated ...
(Date:4/28/2016)... 2016  Marking its one year anniversary since ... cancer risk test, Color Genomics announced ... highly impact the most common hereditary cancers affecting ... Test analyzes hereditary cancer risks for breast, colorectal, ... The Color Test is physician ordered and includes ...
(Date:4/28/2016)... , April 28, 2016 ... insights on healthcare, announced today that it has been ... Cool Vendor in Life Sciences, 2016, ... 2016.  The report focuses on life-science- oriented analytics, algorithms ... from patients and doctors, confirm medication ingestion, and analyze ...
Breaking Medicine Technology: